You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Adoption of Guideline-Recommended Care in Heart Failure: Two-Year Results From IMPROVE HF

  • Authors: Anne B. Curtis, MD; Gregg C. Fonarow, MD
  • CME Released: 9/1/2010
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 9/1/2011
Start Activity


Target Audience and Goal Statement

This program is intended for cardiologists, electrophysiologists, and other healthcare professionals involved in the diagnosis and management of patients with heart failure (HF).

The purpose of this activity is to update clinicians on the use of guideline-based care in patients with HF.

Upon completion of this activity, participants will be able to:

  1. Discuss how to consistently deliver evidenced-based, guideline-recommended care to patients with HF


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Any use of trade names in this program is for reference purposes only. No promotion of particular products or devices should be inferred.


Moderator(s)

  • Anne B. Curtis, MD

    Charles and Mary Bauer Professor of Medicine; Chair, Department of Medicine, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York

    Disclosures

    Disclosure: Anne B. Curtis, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Medtronic, Inc.; St. Jude Medical; Biosense Webster; sanofi-aventis
    Served as a speaker or a member of a speakers bureau for: Medtronic, Inc.; St. Jude Medical; sanofi-aventis
    Received grants for clinical research from: Medtronic, Inc.; St. Jude Medical

    Dr. Curtis does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the US Food and Drug Administration (FDA) for use in the United States.

    Dr. Curtis does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist(s)

  • Gregg C. Fonarow, MD

    Professor of Medicine, Director, Ahmanson-UCLA Cardiomyopathy Center; Co-Director, UCLA Preventative Cardiology Program; Associate Chief, UCLA Division of Cardiology; The Eliot Corday Chair in Cardiovascular Medicine and Science, David Geffen School of Medicine at UCLA, Los Angeles, California

    Disclosures

    Disclosure: Gregg C. Fonarow, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Novartis Pharmaceuticals Corporation; Pfizer Inc.
    Served as a speaker or a member of a speakers bureau for: Medtronic, Inc.

    Dr. Fonarow does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr. Fonarow does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

  • Javier F. Negrón, PhD

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Javier Negrón, PhD, has disclosed no relevant financial relationships.

Steering Committee

  • Sana Al-Khatib, MD

    Disclosures

    Disclosure: Sana Al-Khatib, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: sanofi-aventis
    Served as a speaker or a member of a speakers bureau for: Biotronik; Medtronic, Inc.
    Received grants for clinical research from: Bristol-Myers Squibb Company; Biotronik; Medtronic, Inc.

  • David L. Hayes, MD

    Disclosures

    Disclosure: David L. Hayes, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Boston Scientific; St. Jude Medical
    Served as a speaker or a member of a speakers bureau for: Boston Scientific; St. Jude Medical; Medtronic, Inc.; Sorin Group; Biotronik

  • Francis E. Marchlinski, MD

    Disclosures

    Disclosure: Francis E. Marchlinski, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Biosense Webster, IncServed as a speaker or a member of a speakers bureau for: Boston Scientific; Medtronic, Inc.; St. Jude Medical; Biosense Webster, Inc.
    Received grants for clinical research from: Biosense Webster, Inc.; St. Jude Medical; Medtronic, Inc.; Boston Scientific

  • Eric N. Prystowsky, MD

    Disclosures

    Disclosure: Eric N. Prystowsky, MD, has disclosed the following relevant financial relationships:
    Served as an advisor/consultant for: Medtronic, Inc.; sanofi-aventis; Boehringer Ingelheim Pharmaceuticals, Inc.; Stereotaxis, Inc.
    Received grants for clinical research: sanofi-aventis
    Owns stock, stock options, or bonds from: CardioNet, Stereotaxis, Inc.
    Served on the Board of Directors for: Stereotaxis, Inc.; CardioNet, Inc.

CME Reviewer(s)

  • Laurie E. Scudder, DNP, NP

    Accreditation Coordinator, Continuing Professional Education Department, Medscape, LLC; Clinical Assistant Professor, School of Nursing and Allied Health, George Washington University, Washington, DC; Nurse Practitioner, School-Based Health Centers, Baltimore City Public Schools, Baltimore, Maryland

    Disclosures

    Disclosure: Laurie E. Scudder, DNP, NP, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. MedscapeCME encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME

Adoption of Guideline-Recommended Care in Heart Failure: Two-Year Results From IMPROVE HF

Authors: Anne B. Curtis, MD; Gregg C. Fonarow, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 9/1/2010

Valid for credit through: 9/1/2011

processing....

Sudden cardiac arrest is a significant cause of mortality, accounting for approximately 180,000 to 460,000 deaths each year in the United States and up to 8.5 million deaths annually worldwide. Furthermore, 5.8 million Americans are currently affected by heart failure (HF). Medical therapies help reduce the incidence of arrhythmias and control the clinical conditions that contribute to coronary disease; however, in both arrhythmias and HF, pharmacologic therapy has limited effectiveness and, as the conditions progress, electronic devices will usually be required to maintain cardiac functionality. Device-based cardiac rhythm management has established benefit for patients at high sudden cardiac arrest risk. This technology continues to evolve, with new clinical trials potentially expanding the target populations and advances in device capabilities providing greater patient monitoring potential. Healthcare professionals must be prepared for developments in device-based cardiac rhythm management that may influence current best practices.

This feature requires the newest version of Flash. You can download it here.
  • Print